Allspring Global Investments Holdings LLC Lowers Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Allspring Global Investments Holdings LLC lessened its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 20.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,618 shares of the specialty pharmaceutical company’s stock after selling 4,011 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Jazz Pharmaceuticals were worth $1,933,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Pacer Advisors Inc. boosted its position in Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock worth $272,713,000 after purchasing an additional 115,102 shares in the last quarter. Franklin Resources Inc. boosted its position in Jazz Pharmaceuticals by 4.6% in the 3rd quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock worth $124,208,000 after purchasing an additional 48,708 shares in the last quarter. Thompson Siegel & Walmsley LLC boosted its position in Jazz Pharmaceuticals by 8.3% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 781,215 shares of the specialty pharmaceutical company’s stock worth $87,035,000 after purchasing an additional 59,685 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 8.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 531,710 shares of the specialty pharmaceutical company’s stock worth $59,238,000 after buying an additional 42,587 shares during the period. Finally, Systematic Financial Management LP raised its stake in shares of Jazz Pharmaceuticals by 11.7% during the 3rd quarter. Systematic Financial Management LP now owns 283,977 shares of the specialty pharmaceutical company’s stock worth $31,638,000 after buying an additional 29,647 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $136.01 on Friday. The business has a 50-day moving average of $124.85 and a 200 day moving average of $117.99. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $138.27. The stock has a market capitalization of $8.22 billion, a price-to-earnings ratio of 19.16, a price-to-earnings-growth ratio of 1.03 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Wall Street Analyst Weigh In

JAZZ has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Piper Sandler reaffirmed an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, TD Cowen reduced their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research note on Thursday, November 7th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $180.33.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $121.17, for a total value of $242,340.00. Following the completion of the transaction, the chief executive officer now owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 5,053 shares of company stock worth $617,442 in the last three months. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.